Welcome to our dedicated page for Adm Tronics news (Ticker: ADMT), a resource for investors and traders seeking the latest updates and insights on Adm Tronics stock.
ADM Tronics Unlimited, Inc. (OTCQB: ADMT) is regularly featured in company news as a technology-based developer and manufacturer of proprietary electronic medical devices, contract engineering and manufacturing services, and eco-friendly water-based formulations. Its releases provide updates on financial performance, research and development activity, and progress on key medical and veterinary technologies.
Recent ADMT news has focused on quarterly and annual financial results, where the company discusses revenues, gross profit, operating expenses, and income or loss from operations across segments such as electronics, engineering services, and chemical-related activities. These reports often highlight trends in revenue growth or declines, the impact of inflation and component supply on margins, and the effect of R&D priorities on segment performance.
A central theme in ADMT’s news coverage is the development and commercialization of its Sonotron® technology. The company reports ongoing R&D on a human medical version of Sonotron, a non-invasive therapeutic device intended for musculoskeletal pain conditions, and its intention to pursue a 510(k) submission to the FDA once development is complete. ADMT also issues updates on Vet-Sonotron®, the veterinary version of this technology, including completion of R&D, commencement of production, initial commercialization, pre-orders, distributor relationships, and presentations at industry webinars and shareholder video calls.
Investors and observers following ADMT news can expect coverage of earnings releases, segment performance, R&D milestones for Sonotron and Vet-Sonotron, commentary on operating conditions, and information about the company’s contract medical device engineering and manufacturing services. This news page aggregates such announcements to help readers track ADMT’s disclosed developments over time.
ADM Tronics Unlimited, Inc. (ADMT) announced its participation in the Lytham Partners Summer 2021 Investor Conference, scheduled from June 14 to June 16, 2021. President Andre DiMino will be available for virtual one-on-one meetings during the event, where he aims to discuss the company's activities and developments. ADMT specializes in designing, developing, and manufacturing electronic medical devices at its FDA-Registered and ISO-Certified facility in Northvale, NJ, with a unique capability to handle all phases of medical device development in-house.
ADM Tronics Unlimited, Inc. (ADMT) has partnered with Ventis Medical, Inc. to manufacture and support the regulatory compliance for their Ventis VM-2000 Ventilator, designed for emergency use. This ventilator aims to provide a low-cost and user-friendly solution for critical healthcare needs, addressing situations where traditional ventilators are unavailable. ADMT will utilize its FDA-Registered facility in New Jersey for the manufacturing process, actively working with VMI to meet necessary regulatory requirements for both US and international distribution.
ADM Tronics Unlimited (ADMT) has secured the Infectious Disease Prevention Training Certification from the NJBIA, establishing a comprehensive disease prevention plan that aligns with WHO and CDC guidelines. This certification emphasizes ADMT's commitment to employee and community health amidst the COVID-19 pandemic while maintaining operational continuity. The company continues its focus on developing medical technologies at its FDA-Registered facility in Northvale, NJ. ADMT specializes in electronic medical devices and offers complete design and manufacturing services.
ADM Tronics Unlimited, Inc. (ADMT) reported a 5% decrease in revenues for the third fiscal quarter ended December 31, 2020, totaling $762,644, down from $805,126 in the same quarter of 2019. For the nine-month period, revenues decreased by 13% to $2,258,822, primarily due to the impact of COVID-19 on customer operations and reduced medical procedures. Despite these challenges, manufacturing revenues grew by 10%. ADMT continues investing in research and development for proprietary medical technologies, seeking future growth opportunities.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) reported its second fiscal quarter results for FY 2021, ending September 30, 2020. Revenues increased 63% to $927,085 from $569,093 in Q1, though down 3% year-over-year. Manufacturing revenues grew by 41% and 57% for Q2 and YTD, respectively, despite pandemic challenges impacting engineering and chemical segments. Operational income was $5,366, improved from a loss of $43,748 last year, while losses for the first half were $178,504. ADMT continues to invest in proprietary medical technology development.
ADM Tronics Unlimited, Inc. (ADMT) announced that Origin, Inc. submitted an Investigational Device Exemption (IDE) application to the FDA for clinical studies using its nitric oxide (NO) technology to treat COVID-19. ADMT has developed the IonoJet™, which delivers NO generated from room air. Origin’s Chairman noted the potential of NO in combating coronaviruses and acknowledged ADMT's crucial role in their development. ADMT's president expressed excitement about the technology's potential impact on the pandemic. ADMT specializes in medical devices and eco-friendly formulations.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) reported its Q1 results for FY 2021, with revenues of $569,093, down 31% from $830,821 in the same quarter last year. The electronic segment experienced an 86% increase in revenue to $288,062, but the engineering and chemical segments declined by 58%, totaling $281,031. The net loss for the quarter was $115,736, a reversal from a net income of $52,769 in Q1 FY 2020. ADMT continues to invest in R&D, particularly in its proprietary Sonotron technology, amidst challenges posed by the COVID-19 pandemic.